Literature DB >> 2194713

Characterization of Candida albicans epidermolytic proteases and their role in yeast-cell adherence to keratinocytes.

E A el-Maghrabi1, D M Dixon, J W Burnett.   

Abstract

Epidermolytic proteases were partially purified from six strains of Candida albicans, four of which were isolated from patients with cutaneous diseases. Two of the strains exhibited a unique time-course of enzyme production compared to that previously reported, with detectable epidermolytic protease levels being significantly delayed. All epidermolytic proteases had pH and temperature optima of 4-4.5 and 35-37 degrees C, respectively. These conditions are consistent with the microenvironment of human skin, a habitat where an epidermolytic protease would appear to be an important advantage to the yeast. Candida epidermolytic proteases were more active against a substrate of normal human epidermis than that obtained from psoriatic patients. When human epidermis replaced bovine serum albumin as the protein source within the culture medium, the epidermolytic activity of the resultant enzyme was reduced by 9 and 25% for normal and psoriatic epidermis substrates, respectively. The proteases were found to contain major protein bands at 42 and 66 kDa. The ability of these same Candida strains to adhere to human epidermal cells was studied and found to be optimal at 35-37 degrees C within neutral pH values. Pepstatin, bovine brain gangliosides, and convalescent human serum all interfered with the adherence of the yeast to epidermal cells. A higher yeast-epidermal-cell adherence for Candida was demonstrated on normal rather than psoriatic epidermal cells, and after treating the cells with partially purified Candida protease.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2194713     DOI: 10.1111/j.1365-2230.1990.tb02069.x

Source DB:  PubMed          Journal:  Clin Exp Dermatol        ISSN: 0307-6938            Impact factor:   3.470


  9 in total

1.  Secreted aspartyl proteinases and interactions of Candida albicans with human endothelial cells.

Authors:  A S Ibrahim; S G Filler; D Sanglard; J E Edwards; B Hube
Journal:  Infect Immun       Date:  1998-06       Impact factor: 3.441

Review 2.  Serologic response to cell wall mannoproteins and proteins of Candida albicans.

Authors:  J P Martínez; M L Gil; J L López-Ribot; W L Chaffin
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

3.  Disruption of each of the secreted aspartyl proteinase genes SAP1, SAP2, and SAP3 of Candida albicans attenuates virulence.

Authors:  B Hube; D Sanglard; F C Odds; D Hess; M Monod; W Schäfer; A J Brown; N A Gow
Journal:  Infect Immun       Date:  1997-09       Impact factor: 3.441

4.  Role of aspartic proteases in disseminated Candida albicans infection in mice.

Authors:  K Fallon; K Bausch; J Noonan; E Huguenel; P Tamburini
Journal:  Infect Immun       Date:  1997-02       Impact factor: 3.441

Review 5.  The role of Candida albicans secreted aspartic proteinase in the development of candidoses.

Authors:  L Hoegl; M Ollert; H C Korting
Journal:  J Mol Med (Berl)       Date:  1996-03       Impact factor: 4.599

6.  Mechanisms of adherence of Candida albicans to cultured human epidermal keratinocytes.

Authors:  M W Ollert; R Söhnchen; H C Korting; U Ollert; S Bräutigam; W Bräutigam
Journal:  Infect Immun       Date:  1993-11       Impact factor: 3.441

7.  Increased expression of Candida albicans secretory proteinase, a putative virulence factor, in isolates from human immunodeficiency virus-positive patients.

Authors:  M W Ollert; C Wende; M Görlich; C G McMullan-Vogel; M Borg-von Zepelin; C W Vogel; H C Korting
Journal:  J Clin Microbiol       Date:  1995-10       Impact factor: 5.948

Review 8.  Candida albicans secreted aspartyl proteinases in virulence and pathogenesis.

Authors:  Julian R Naglik; Stephen J Challacombe; Bernhard Hube
Journal:  Microbiol Mol Biol Rev       Date:  2003-09       Impact factor: 11.056

9.  Effect of pepstatin A on the virulence factors of Candida albicans strains isolated from vaginal environment of patients in three different clinical conditions.

Authors:  M E L Consolaro; A Gasparetto; T I E Svidzinski; R M Peralta
Journal:  Mycopathologia       Date:  2006-08       Impact factor: 3.785

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.